Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
44 hedge funds and large institutions have $300M invested in Centessa Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
7% more funds holding
Funds holding: 41 → 44 (+3)
2.85% more ownership
Funds ownership: 76.38% → 79.24% (+2.9%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
14% less capital invested
Capital invested by funds: $350M → $300M (-$49.8M)
56% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$13.5M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$11.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.19M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$1.11M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$572K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$5.49M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$5.2M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.37M |
| 4 |
JP Morgan Chase
New York
|
-$800K |
| 5 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$703K |
CNTA Hedge Fund Activity: Q3 2022 in Review
44 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q3 2022, worth a combined $300M — down 14% from $350M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CNTA positions and 3 closed out — a net gain of 3 holders — while 7 added to existing stakes and 16 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $13.5M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $5.49M sold.
- 44 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q3 2022, up from 41 in Q2 2022.
- Funds reported $300M of Centessa Pharmaceuticals stock for Q3 2022, down 14% quarter-over-quarter.
- 6 funds opened new Centessa Pharmaceuticals positions in Q3 2022 and 3 closed out, a net change of +3 holders.
- The largest Centessa Pharmaceuticals buyer in Q3 2022 was EcoR1 Capital, an estimated $13.5M added.
- The largest Centessa Pharmaceuticals seller in Q3 2022 was Baker Bros. Advisors, an estimated $5.49M sold.
Based on aggregated 13F filings for Q3 2022.